COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Safety Study of MGD006 in Relapsed/Refractory Acute Myeloid Leukemia (AML) or Intermediate-2/High Risk MDS

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT02152956
Recruitment Status : Recruiting
First Posted : June 2, 2014
Last Update Posted : April 27, 2020
Information provided by (Responsible Party):

Brief Summary:
The primary goal of this Phase 1/2, dose-escalation study, is to determine the maximum tolerated dose level of flotetuzumab (MGD006) in patients with AML whose disease is not expected to benefit from cytotoxic chemotherapy. Studies will also be done to see how the drug acts in the body (pharmacokinetics [PK], pharmacodynamics) and to evaluate potential anti-tumor activity of flotetuzumab.

Condition or disease Intervention/treatment Phase
AML Drug: Flotetuzumab Phase 1 Phase 2

Detailed Description:

Open-label, multi-dose, single-arm, multi-center, Phase 1/2, dose-escalation study to define a maximum tolerated dose and schedule (MTDS), describe preliminarily safety, and to assess PK, immunogenicity, immunomodulatory activity, and potential anti-tumor activity of flotetuzumab in patients with AML whose disease is not expected to benefit from cytotoxic chemotherapy.

This study is designed in three segments: the Single Patient Dose Escalation Segment, followed by the Multi-Patient Dose Escalation Segment and the MTDS Expansion Cohort Segment.

The Multi-Patient Dose Escalation Segment will employ a classical 3+3 scheme to examine a series of increasing dose escalations in cohorts of patients with AML.

Any Dose Escalation Cohort not exceeding the maximum tolerated dose may be expanded to include up to 15 patients for further evaluation of the safety, PK, and preliminary anti-tumor activity of flotetuzumab. Once the MTDS is established, the cohort of patients treated at that dose/schedule or a lower dose, will be expanded with the addition of up to 120 AML patients.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 179 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 1/2, First in Human, Dose Escalation Study of MGD006, a CD123 x CD3 Dual Affinity Re-Targeting (DART®) Bi-Specific Antibody Based Molecule, in Patients With Relapsed or Refractory AML or Intermediate-2/High Risk MDS
Actual Study Start Date : June 9, 2014
Estimated Primary Completion Date : December 2020
Estimated Study Completion Date : April 2021

Arm Intervention/treatment
Experimental: Flotetuzumab
CD123 x CD3 bispecific DART® antibody
Drug: Flotetuzumab
Flotetuzumab is a CD123 x CD3 bispecific antibody-based molecular construct referred to as a DART® molecule.
Other Name: MGD006

Primary Outcome Measures :
  1. Occurrence of dose limiting toxicity [ Time Frame: Cycle 1 of a 28 day cycle. ]
    • Maximum Tolerated Dose/Schedule: the MTDS will be defined as the highest dose/schedule administered during any Cohort in the study at which the incidence of DLT is < 33% during the first cycle of MGD006 treatment.

Secondary Outcome Measures :
  1. Occurrence of adverse events (AEs) and serious adverse events (SAEs) [ Time Frame: Up to 7 months ]
  2. Occurrence of anti-leukemic activity [ Time Frame: Every 28 days ]
  3. Measure the pharmacokinetics (PK) of flotetuzumab [ Time Frame: Cycle 1 through end of treatment (28 day cycles) ]
  4. Occurrence of anti-drug antibody [ Time Frame: Cycle 1 through end of treatment (28 day cycles) ]

  5. Overall survival [ Time Frame: Time from first dose to death from any cause; assessed up to 2 years ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Confirmed diagnosis of primary or secondary AML [any subtype except acute promyelocytic leukemia (APL)] according to World Health Organization (WHO) classification
  • Patients with AML must be unlikely to benefit from recommended standard of care defined by any one of the following criteria:

    a. AML refractory to ≥ 2 (or ≥ 1 for patients > 65 years of age) induction attempts, including but not limited to the following:

    i. AML refractory to ≥ 1 intensive induction attempt(s), per institution, including high- and standard-dose cytarabine ± an anthracyclines/anthracenedione ± an anti-metabolite with or without growth factor or targeted therapy,

ii. for adults who are age 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy, AML refractory to ≥ 2 lower intensity induction attempts including Bcl-2 or Hedgehog inhibitors with azacitidine/decitabine/LDAC or available targeted therapies such as FLT3/IDH1/IDH2/anti-CD33 antibodies;

b. AML in 1st relapse with initial CR duration < 6 months,

c. a maximum of up to 2 prior salvage attempts is allowed.

  • Eastern Cooperative Oncology Group (ECOG) performance status ≤2
  • Life expectancy of at least 4 weeks
  • Peripheral blast count </= 20,000/mm3 at the time of registration
  • Acceptable laboratory parameters and adequate organ reserve

Exclusion Criteria:

  • History of allogeneic stem cell transplantation.
  • Prior treatment with an anti-CD123-directed agent, with the exception of patients with relapsed disease after flotetuzumab treatment
  • Need for concurrent other cytoreductive chemotherapy
  • Any prior history of or suspected current autoimmune disorders (with the exception of vitiligo, resolved childhood atopic dermatitis, prior Grave's disease now euthyroid clinically and by laboratory testing)
  • Second primary malignancy that requires active therapy. Adjuvant hormonal therapy is allowed.
  • Antitumor therapy or investigational agent within 14 days or 5 half-lives of Cycle 1 Day 1
  • Requirement, at the time of study entry, for concurrent steroids > 10 mg/day of oral prednisone or the equivalent, except steroid inhaler, nasal spray or ophthalmic solution
  • Use of immunosuppressant medications in the 2 weeks of Cycle 1 Day 1
  • Use of granulocyte colony stimulating or granulocyte-macrophage colony stimulating factor in the 2 weeks of Cycle 1 Day 1
  • Known central nervous system (CNS) leukemia.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT02152956

Layout table for location contacts
Contact: Kathy Tran

Show Show 26 study locations
Sponsors and Collaborators
Layout table for investigator information
Principal Investigator: John DiPersio, MD, PhD Washington University School of Medicine
Study Director: Jan Davidson-Moncada, MD, PhD MacroGenics
Principal Investigator: Norbert Vey, MD Institute Paoli-Calmettes
Layout table for additonal information
Responsible Party: MacroGenics Identifier: NCT02152956    
Other Study ID Numbers: CP-MGD006-01
First Posted: June 2, 2014    Key Record Dates
Last Update Posted: April 27, 2020
Last Verified: April 2020

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by MacroGenics: